表紙
市場調查報告書

神經營養性角膜炎的全球市場:產業分析,市場規模,成長,趨勢,預測 - 治療類型(投藥,外科的治療),階段,各地區

Neurotrophic Keratitis Market (Treatment Type: Drugs and Surgical Intervention ; and Application: Stage I, Stage II, and Stage III) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

出版商 Transparency Market Research 商品編碼 930862
出版日期 內容資訊 英文 182 Pages
商品交期: 最快1-2個工作天內
價格
神經營養性角膜炎的全球市場:產業分析,市場規模,成長,趨勢,預測 - 治療類型(投藥,外科的治療),階段,各地區 Neurotrophic Keratitis Market (Treatment Type: Drugs and Surgical Intervention ; and Application: Stage I, Stage II, and Stage III) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027
出版日期: 2020年02月26日內容資訊: 英文 182 Pages
簡介

本報告提供全球神經營養性角膜炎市場調查,提供市場概要,各治療類型·階段·各地區的市場規模的變化與預測,成長率,銷售額·收益趨勢,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 市場定義和範圍
  • 市場區隔
  • 主要的調查目的
  • 調查亮點

第2章 前提條件與調查手法

第3章 摘要整理

第4章 市場概要

  • 簡介
    • 治療類型定義
  • 概要
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 市場分析與預測
    • 收益額的預測
  • 波特的五力分析

第5章 市場預測

  • 疾病的盛行率·罹患率:全體·各地各國
  • 開發平台分析
  • 產業的主要趨勢

第6章 全球神經營養性角膜炎市場分析與預測:各治療類型

  • 簡介和定義
  • 主要調查結果與趨勢
  • 市場規模:各治療類型(實際成果值·預測值)
    • 投藥
    • 外科的治療
  • 市場魅力分析:各治療類型

第7章 全球神經營養性角膜炎市場分析與預測:各階段

  • 簡介和定義
  • 市場規模:各階段(實際成果值·預測值)
    • 第1階段
    • 第2階段
    • 第3階段
  • 市場魅力分析:各階段

第8章 全球神經營養性角膜炎市場分析與預測:各地區

  • 主要調查結果
  • 市場規模:各地區(實際成果值·預測值)
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲
  • 市場魅力分析:各地區

第9章 北美

第10章 歐洲

第11章 亞太地區

第12章 南美

第13章 中東·非洲

第14章 競爭情形

  • 競爭矩陣
  • 企業的市場佔有率
  • 企業簡介
    • Dompe farmaceutici SpA
    • Allergan
    • ReGenTree, LLC
    • Alcon
    • Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
    • CONTACARE
    • ROHTO製藥
    • Pfizer, Inc.
    • Neuroptika
    • 參天製藥
    • Johnson & Johnson
    • Grand Pharma (China) Co., Ltd.
    • Zhejiang CONBA Pharmaceutical Co., Ltd.
目錄
Product Code: TMRGL72848

Scope of the Report

TMR's report on the global neurotrophic keratitis market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period of 2019-2027. The report provides the revenue of the global neurotrophic keratitis market for the period 2017-2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) of the global neurotrophic keratitis market during the forecast period.

The report has been prepared after an extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global neurotrophic keratitis market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various phenomenon in the global neurotrophic keratitis market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on changing competitive dynamics in the global neurotrophic keratitis market. These indices serve as valuable tools for existing players in the neurotrophic keratitis market as well as for entities interested in entering the global market.

The report delves into the competitive landscape of the global neurotrophic keratitis market. Key players operating in the global neurotrophic keratitis market have been identified, and each one of these has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global neurotrophic keratitis market that have been profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Neurotrophic Keratitis Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Treatment Type Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Neurotrophic Keratitis Market Analysis and Forecast, 2017-2027
    • 4.4.1. Market Revenue Projections (US$ Mn)
  • 4.5. Porter's Five Force Analysis

5. Market Outlook

  • 5.1. Disease Prevalence & Incidence Rate globally with key countries / Region
  • 5.2. Pipeline Analysis
  • 5.3. Key Industry Developments

6. Global Neurotrophic Keratitis Market Analysis and Forecast, by Treatment Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Treatment Type, 2017-2027
    • 6.3.1. Drugs
      • 6.3.1.1. Artificial Tears
      • 6.3.1.2. Recombinant Human Nerve Growth Factors Eye Drop
      • 6.3.1.3. Oral Antibiotics
      • 6.3.1.4. Bandage Contact Lens
      • 6.3.1.5. Others
    • 6.3.2. Surgical Intervention
      • 6.3.2.1. Tarsorrhaphy
      • 6.3.2.2. Amniotic Membrane Transplantation
      • 6.3.2.3. Others
  • 6.4. Market Attractiveness, by Treatment Type

7. Global Neurotrophic Keratitis Market Analysis and Forecast, by Stage

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Stage, 2017-2027
    • 7.3.1. Stage I
    • 7.3.2. Stage II
    • 7.3.3. Stage III
  • 7.4. Market Attractiveness Analysis, by Stage

8. Global Neurotrophic Keratitis Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness Analysis, by Country/Region

9. North America Neurotrophic Keratitis Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast By Treatment Type, 2017-2027
    • 9.2.1. Drugs
      • 9.2.1.1. Artificial Tears
      • 9.2.1.2. Recombinant Human Nerve Growth Factors Eye Drop
      • 9.2.1.3. Oral Antibiotics
      • 9.2.1.4. Bandage Contact Lens
      • 9.2.1.5. Others
    • 9.2.2. Surgical Intervention
      • 9.2.2.1. Tarsorrhaphy
      • 9.2.2.2. Amniotic Membrane Transplantation
      • 9.2.2.3. Others
  • 9.3. Market Value Forecast, by Stage, 2017-2027
    • 9.3.1. Stage I
    • 9.3.2. Stage II
    • 9.3.3. Stage III
  • 9.4. Market Value Forecast, by Country, 2017-2027
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Treatment Type
    • 9.5.2. By Stage
    • 9.5.3. By Country

10. Europe Neurotrophic Keratitis Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Treatment Type, 2017-2027
    • 10.2.1. Drugs
      • 10.2.1.1. Artificial Tears
      • 10.2.1.2. Recombinant Human Nerve Growth Factors Eye Drop
      • 10.2.1.3. Oral Antibiotics
      • 10.2.1.4. Bandage Contact Lens
      • 10.2.1.5. Others
    • 10.2.2. Surgical Intervention
      • 10.2.2.1. Tarsorrhaphy
      • 10.2.2.2. Amniotic Membrane Transplantation
      • 10.2.2.3. Others
  • 10.3. Market Value Forecast, by Stage, 2017-2027
    • 10.3.1. Stage I
    • 10.3.2. Stage II
    • 10.3.3. Stage III
  • 10.4. Market Value Forecast, by Country/Sub-region, 2017-2027
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Spain
    • 10.4.5. Italy
    • 10.4.6. Rest of Europe
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Treatment Type
    • 10.5.2. By Stage
    • 10.5.3. By Country/Sub-region

11. Asia Pacific Neurotrophic Keratitis Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Treatment Type, 2017-2027
    • 11.2.1. Drugs
      • 11.2.1.1. Artificial Tears
      • 11.2.1.2. Recombinant Human Nerve Growth Factors Eye Drop
      • 11.2.1.3. Oral Antibiotics
      • 11.2.1.4. Bandage Contact Lens
      • 11.2.1.5. Others
    • 11.2.2. Surgical Intervention
      • 11.2.2.1. Tarsorrhaphy
      • 11.2.2.2. Amniotic Membrane Transplantation
      • 11.2.2.3. Others
  • 11.3. Market Value Forecast, by Stage, 2017-2027
    • 11.3.1. Stage I
    • 11.3.2. Stage II
    • 11.3.3. Stage III
  • 11.4. Market Value Forecast, by Country/Sub-region, 2017-2027
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Treatment Type
    • 11.5.2. By Stage
    • 11.5.3. By Country/Sub-region

12. Latin America Neurotrophic Keratitis Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Treatment Type, 2017-2027
    • 12.2.1. Drugs
      • 12.2.1.1. Artificial Tears
      • 12.2.1.2. Recombinant Human Nerve Growth Factors Eye Drop
      • 12.2.1.3. Oral Antibiotics
      • 12.2.1.4. Bandage Contact Lens
      • 12.2.1.5. Others
    • 12.2.2. Surgical Intervention
      • 12.2.2.1. Tarsorrhaphy
      • 12.2.2.2. Amniotic Membrane Transplantation
      • 12.2.2.3. Others
  • 12.3. Market Value Forecast, by Stage, 2017-2027
    • 12.3.1. Stage I
    • 12.3.2. Stage II
    • 12.3.3. Stage III
  • 12.4. Market Value Forecast, by Country/Sub-region, 2017-2027
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Treatment Type
    • 12.5.2. By Stage
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Neurotrophic Keratitis Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Treatment Type, 2017-2027
    • 13.2.1. Drugs
      • 13.2.1.1. Artificial Tears
      • 13.2.1.2. Recombinant Human Nerve Growth Factors Eye Drop
      • 13.2.1.3. Oral Antibiotics
      • 13.2.1.4. Bandage Contact Lens
      • 13.2.1.5. Others
    • 13.2.2. Surgical Intervention
      • 13.2.2.1. Tarsorrhaphy
      • 13.2.2.2. Amniotic Membrane Transplantation
      • 13.2.2.3. Others
  • 13.3. Market Value Forecast, by Stage, 2017-2027
    • 13.3.1. Stage I
    • 13.3.2. Stage II
    • 13.3.3. Stage III
  • 13.4. Market Value Forecast, by Country/Sub-region, 2017-2027
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Treatment Type
    • 13.5.2. By Stage
    • 13.5.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 14.2. Market Share/Position Analysis, by Company, 2018
  • 14.3. Company Profiles
    • 14.3.1. Dompe farmaceutici S.p.A.
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Growth Strategies
      • 14.3.1.3. SWOT Analysis
    • 14.3.2. Allergan
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Growth Strategies
      • 14.3.2.3. SWOT Analysis
    • 14.3.3. ReGenTree, LLC
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Growth Strategies
      • 14.3.3.3. SWOT Analysis
    • 14.3.4. Alcon
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Growth Strategies
      • 14.3.4.3. SWOT Analysis
    • 14.3.5. Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Growth Strategies
      • 14.3.5.3. SWOT Analysis
    • 14.3.6. CONTACARE
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Growth Strategies
      • 14.3.6.3. SWOT Analysis
    • 14.3.7. ROHTO Pharmaceutical Co., Ltd.
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Growth Strategies
      • 14.3.7.3. SWOT Analysis
    • 14.3.8. Pfizer, Inc.
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Growth Strategies
      • 14.3.8.3. SWOT Analysis
    • 14.3.9. Neuroptika
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Growth Strategies
      • 14.3.9.3. SWOT Analysis
    • 14.3.10. Santen Pharmaceutical Co., Ltd.
      • 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.10.2. Growth Strategies
      • 14.3.10.3. SWOT Analysis
    • 14.3.11. Johnson & Johnson
      • 14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.11.2. Growth Strategies
      • 14.3.11.3. SWOT Analysis
    • 14.3.12. Grand Pharma (China) Co., Ltd.
      • 14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.12.2. Growth Strategies
      • 14.3.12.3. SWOT Analysis
    • 14.3.13. Zhejiang CONBA Pharmaceutical Co., Ltd.
      • 14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.13.2. Growth Strategies
      • 14.3.13.3. SWOT Analysis

List of Tables

  • Table 01: Neurotrophic Keratitis Pipeline Analysis - Phase III and Phase II
  • Table 02: Neurotrophic Keratitis Pipeline Analysis - Phase I
  • Table 03: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2027
  • Table 04: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017-2027
  • Table 05: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017-2027
  • Table 06: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017-2027
  • Table 07: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Region, 2017-2027
  • Table 08: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Country, 2017-2027
  • Table 09: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2027
  • Table 10: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017-2027
  • Table 11: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017-2027
  • Table 12: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017-2027
  • Table 13: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 14: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2027
  • Table 15: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017-2027
  • Table 16: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017-2027
  • Table 17: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017-2027
  • Table 18: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 19: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2027
  • Table 20: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017-2027
  • Table 21: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017-2027
  • Table 22: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017-2027
  • Table 23: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 24: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2027
  • Table 25: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017-2027
  • Table 26: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017-2027
  • Table 27: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017-2027
  • Table 28: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 29: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2027
  • Table 30: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Drugs, 2017-2027
  • Table 31: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Surgical Intervention, 2017-2027
  • Table 32: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast, by Stage, 2017-2027

List of Figures

  • Figure 01: Global Neurotrophic Keratitis Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027
  • Figure 02: Global Neurotrophic Keratitis Market Value (US$ Mn), by Treatment Type, 2018 (A)
  • Figure 03: Global Neurotrophic Keratitis Market, Top 3 Trends, 2018
  • Figure 04: Market Overview
  • Figure 05: Global Neurotrophic Keratitis Market Value (US$ Mn) Forecast, 2017-2027
  • Figure 06: Global Neurotrophic Keratitis Market Value Share, by Treatment Type, 2018
  • Figure 07: Global Neurotrophic Keratitis Market Value Share, by Stage, 2018
  • Figure 08: Global Neurotrophic Keratitis Market Value Share, by Region, 2018
  • Figure 09: Global Neurotrophic Keratitis Market Value Share, by Drugs, 2018
  • Figure 10: Global Neurotrophic Keratitis Market Value Share, by Surgical Intervention, 2018
  • Figure 11: Global Neurotrophic Keratitis Market Value Share Analysis, by Treatment Type, 2018 and 2027
  • Figure 12: Global Neurotrophic Keratitis Market Value Share Analysis, by Drugs, 2018 and 2027
  • Figure 13: Global Neurotrophic Keratitis Market Value Share Analysis, by Surgical Intervention, 2018 and 2027
  • Figure 14: Global Neurotrophic Keratitis Market Value (US$ Mn) and Y-o-Y Growth (%), by Drugs, 2017-2027
  • Figure 15: Global Neurotrophic Keratitis Market Value (US$ Mn) and Y-o-Y Growth (%), by Surgical Intervention, 2017-2027
  • Figure 16: Global Neurotrophic Keratitis Market Attractiveness Analysis, by Treatment Type, 2019-2027
  • Figure 17: Global Neurotrophic Keratitis Market Value Share Analysis, by Stage, 2018 and 2027
  • Figure 18: Global Neurotrophic Keratitis Market Value (US$ Mn) and Y-o-Y Growth (%), by Stage I, 2017-2027
  • Figure 19: Global Neurotrophic Keratitis Market Value (US$ Mn) and Y-o-Y Growth (%), by Stage II, 2017-2027
  • Figure 20: Global Neurotrophic Keratitis Market Value (US$ Mn) and Y-o-Y Growth (%), by Stage III, 2017-2027
  • Figure 21: Global Neurotrophic Keratitis Market Attractiveness Analysis, by Stage, 2019-2027
  • Figure 22: Global Neurotrophic Keratitis Market Value Share Analysis, by Region, 2018 and 2027
  • Figure 23: Global Neurotrophic Keratitis Market Attractiveness Analysis, by Region, 2019-2027
  • Figure 24: North America Neurotrophic Keratitis Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2027
  • Figure 25: North America Neurotrophic Keratitis Market Value Share Analysis, by Country, 2018 and 2027
  • Figure 26: North America Neurotrophic Keratitis Market Attractiveness Analysis, by Country, 2019-2027
  • Figure 27: North America Neurotrophic Keratitis Market Value Share Analysis, by Treatment Type, 2018 and 2027
  • Figure 28: North America Neurotrophic Keratitis Market Attractiveness Analysis, by Treatment Type, 2019-2027
  • Figure 29: North America Neurotrophic Keratitis Market Value Share Analysis, by Drugs, 2018 and 2027
  • Figure 30: North America Neurotrophic Keratitis Market Value Share Analysis, by Surgical Intervention, 2018 and 2027
  • Figure 31: North America Neurotrophic Keratitis Market Value Share Analysis, by Stage, 2018 and 2027
  • Figure 32: North America Neurotrophic Keratitis Market Attractiveness Analysis, by Stage, 2019-2027
  • Figure 33: Europe Neurotrophic Keratitis Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2027
  • Figure 34: Europe Neurotrophic Keratitis Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 35: Europe Neurotrophic Keratitis Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 36: Europe Neurotrophic Keratitis Market Value Share Analysis, by Treatment Type, 2018 and 2027
  • Figure 37: Europe Neurotrophic Keratitis Market Attractiveness Analysis, by Treatment Type, 2019-2027
  • Figure 38: Europe Neurotrophic Keratitis Market Value Share Analysis, by Drugs, 2018 and 2027
  • Figure 39: Europe Neurotrophic Keratitis Market Value Share Analysis, by Surgical Intervention, 2018 and 2027
  • Figure 40: Europe Neurotrophic Keratitis Market Value Share Analysis, by Stage, 2018 and 2027
  • Figure 41: Europe Neurotrophic Keratitis Market Attractiveness Analysis, by Stage, 2019-2027
  • Figure 42: Asia Pacific Neurotrophic Keratitis Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2027
  • Figure 43: Asia Pacific Neurotrophic Keratitis Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 44: Asia Pacific Neurotrophic Keratitis Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 45: Asia Pacific Neurotrophic Keratitis Market Value Share Analysis, by Treatment Type, 2018 and 2027
  • Figure 46: Asia Pacific Neurotrophic Keratitis Market Attractiveness Analysis, by Treatment Type, 2019-2027
  • Figure 47: Asia Pacific Neurotrophic Keratitis Market Value Share Analysis, by Drugs, 2018 and 2027
  • Figure 48: Asia Pacific Neurotrophic Keratitis Market Value Share Analysis, by Surgical Intervention, 2018 and 2027
  • Figure 49: Asia Pacific Neurotrophic Keratitis Market Value Share Analysis, by Stage, 2018 and 2027
  • Figure 50: Asia Pacific Neurotrophic Keratitis Market Attractiveness Analysis, by Stage, 2019-2027
  • Figure 51: Latin America Neurotrophic Keratitis Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2027
  • Figure 52: Latin America Neurotrophic Keratitis Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 53: Latin America Neurotrophic Keratitis Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 54: Latin America Neurotrophic Keratitis Market Value Share Analysis, by Treatment Type, 2018 and 2027
  • Figure 55: Latin America Neurotrophic Keratitis Market Attractiveness Analysis, by Treatment Type, 2019-2027
  • Figure 56: Latin America Neurotrophic Keratitis Market Value Share Analysis, by Drugs, 2018 and 2027
  • Figure 57: Latin America Neurotrophic Keratitis Market Value Share Analysis, by Surgical Intervention, 2018 and 2027
  • Figure 58: Latin America Neurotrophic Keratitis Market Value Share Analysis, by Stage, 2018 and 2027
  • Figure 59: Latin America Neurotrophic Keratitis Market Attractiveness Analysis, by Stage, 2019-2027
  • Figure 60: Middle East & Africa Neurotrophic Keratitis Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2027
  • Figure 61: Middle East & Africa Neurotrophic Keratitis Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 62: Middle East & Africa Neurotrophic Keratitis Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 63: Middle East & Africa Neurotrophic Keratitis Market Value Share Analysis, by Treatment Type, 2018 and 2027
  • Figure 64: Middle East & Africa Neurotrophic Keratitis Market Attractiveness Analysis, by Treatment Type, 2019-2027
  • Figure 65: Middle East & Africa Neurotrophic Keratitis Market Value Share Analysis, by Drugs, 2018 and 2027
  • Figure 66: Middle East & Africa Neurotrophic Keratitis Market Value Share Analysis, by Surgical Intervention, 2018 and 2027
  • Figure 67: Middle East & Africa Neurotrophic Keratitis Market Value Share Analysis, by Stage, 2018 and 2027
  • Figure 68: Middle East & Africa Neurotrophic Keratitis Market Attractiveness Analysis, by Stage, 2019-2027
  • Figure 69: Market Position/Ranking Analysis, 2018, by Tier and Size of the Company